JPWO2021113734A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021113734A5 JPWO2021113734A5 JP2022533442A JP2022533442A JPWO2021113734A5 JP WO2021113734 A5 JPWO2021113734 A5 JP WO2021113734A5 JP 2022533442 A JP2022533442 A JP 2022533442A JP 2022533442 A JP2022533442 A JP 2022533442A JP WO2021113734 A5 JPWO2021113734 A5 JP WO2021113734A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- lesion
- cancer
- medicament according
- fiber length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 100
- 230000003902 lesion Effects 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 77
- 239000003814 drug Substances 0.000 claims description 47
- 239000000835 fiber Substances 0.000 claims description 35
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 33
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 33
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 21
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 21
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 21
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 21
- 239000001007 phthalocyanine dye Substances 0.000 claims description 18
- 230000008685 targeting Effects 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 229950009791 durvalumab Drugs 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 210000002865 immune cell Anatomy 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 7
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 238000009169 immunotherapy Methods 0.000 claims description 6
- 230000009401 metastasis Effects 0.000 claims description 6
- 229960003852 atezolizumab Drugs 0.000 claims description 5
- 229950002916 avelumab Drugs 0.000 claims description 5
- 230000001678 irradiating effect Effects 0.000 claims description 5
- 230000035899 viability Effects 0.000 claims description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 4
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000001934 delay Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 4
- 238000001764 infiltration Methods 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 4
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 3
- 238000011394 anticancer treatment Methods 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 101150005623 MSB2 gene Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000000578 peripheral nerve Anatomy 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 201000002060 skeletal muscle cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000000267 smooth muscle cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- QUJXIMWUJGTUEG-CLKUPZDLSA-N 2-[2-[[[(2s,6s,9e,13s)-13-amino-2-[(4-hydroxyphenyl)methyl]-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carbonyl]amino]methyl]phenyl]acetic acid Chemical compound C([C@H]1CC(=O)N[C@@H](CC/C=C/CC[C@@H](C(N1)=O)N)C(=O)NCC=1C(=CC=CC=1)CC(O)=O)C1=CC=C(O)C=C1 QUJXIMWUJGTUEG-CLKUPZDLSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000011453 reproductive organ cancer Diseases 0.000 description 1
- 208000015608 reproductive system cancer Diseases 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945053P | 2019-12-06 | 2019-12-06 | |
| US62/945,053 | 2019-12-06 | ||
| PCT/US2020/063444 WO2021113734A1 (en) | 2019-12-06 | 2020-12-04 | Methods for enhancing immunity and tumor treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505222A JP2023505222A (ja) | 2023-02-08 |
| JP2023505222A5 JP2023505222A5 (https=) | 2023-12-12 |
| JPWO2021113734A5 true JPWO2021113734A5 (https=) | 2023-12-12 |
Family
ID=73856374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533442A Pending JP2023505222A (ja) | 2019-12-06 | 2020-12-04 | 免疫増強および腫瘍処置のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230028062A1 (https=) |
| EP (1) | EP4069300A1 (https=) |
| JP (1) | JP2023505222A (https=) |
| CN (1) | CN115052631A (https=) |
| TW (1) | TW202133886A (https=) |
| WO (1) | WO2021113734A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016308286B2 (en) | 2015-08-18 | 2022-04-07 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
| WO2022182483A1 (en) * | 2021-02-02 | 2022-09-01 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| MX2024010003A (es) * | 2022-02-18 | 2024-09-30 | Rakuten Medical Inc | Moléculas de anticuerpo anti-ligando 1 de muerte programada (pd-l1), polinucleótidos que las codifican y métodos de uso. |
| CN115364238B (zh) * | 2022-08-16 | 2024-02-02 | 山东大学 | 一种阿特珠单抗-mmad结合物及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| CN119564879A (zh) * | 2015-08-18 | 2025-03-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的组合物、联用及相关方法 |
| AU2016308286B2 (en) * | 2015-08-18 | 2022-04-07 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
| RU2740793C2 (ru) | 2016-10-25 | 2021-01-21 | Ракутен Медикал, Инк. | Светорассеивающие устройства для использования в фотоиммунотерапии |
| US10416366B2 (en) | 2016-10-25 | 2019-09-17 | Rakuten Medical, Inc. | Light diffusing devices for use in photoimmunotherapy |
| JP2020508323A (ja) * | 2017-02-23 | 2020-03-19 | ラクテン メディカル インコーポレイテッド | 光免疫療法のための治療用組成物および関連する方法 |
| US20220160871A1 (en) * | 2019-03-29 | 2022-05-26 | Rakuten Medical, Inc. | Methods for photoimmunotherapy and related biomarkers |
| JP7627259B2 (ja) * | 2019-07-30 | 2025-02-05 | ラクテン・メディカル，インコーポレイテッド | 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ） |
-
2020
- 2020-12-04 TW TW109142933A patent/TW202133886A/zh unknown
- 2020-12-04 WO PCT/US2020/063444 patent/WO2021113734A1/en not_active Ceased
- 2020-12-04 US US17/782,111 patent/US20230028062A1/en active Pending
- 2020-12-04 JP JP2022533442A patent/JP2023505222A/ja active Pending
- 2020-12-04 CN CN202080095859.9A patent/CN115052631A/zh active Pending
- 2020-12-04 EP EP20828490.1A patent/EP4069300A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huinen et al. | Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes | |
| Chang et al. | Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy | |
| Hu et al. | Combined radiation therapy and immune checkpoint blockade therapy for breast cancer | |
| Ferris et al. | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation | |
| KR102349056B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| JP2022031638A (ja) | 放射線療法と併用されるｐｄ－１およびｐｄ－ｌ１に対する拮抗薬を用いたがんの治療法 | |
| Al Jarroudi et al. | Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases | |
| Esmaeli et al. | Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma | |
| KR20190120792A (ko) | 폐암의 치료를 위한 항-pd-1 항체 | |
| US20220313822A1 (en) | Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody | |
| CN111132696A (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| WO2019114762A1 (zh) | 免疫效应细胞和辐射联用治疗肿瘤 | |
| WO2021182573A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| WO2023095929A1 (ja) | 悪性腫瘍治療薬 | |
| TW202133886A (zh) | 用於增強免疫及腫瘤治療之方法 | |
| Serre et al. | Brachytherapy: perspectives for combined treatments with immunotherapy | |
| JP7614690B1 (ja) | 腫瘍微小環境をターゲットとする光免疫療法に用いる医薬組成物、治療効果確認のためのマーカー、及び検査方法 | |
| Xia et al. | Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma | |
| JPWO2021113734A5 (https=) | ||
| CN108025190A (zh) | T-dm1难治性癌症患者的syd985治疗 | |
| CN111867598A (zh) | 肿瘤免疫赋活剂 | |
| WO2021182574A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| WO2021182571A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| TW202116353A (zh) | 使用酞菁染料靶向分子結合物之治療方法 | |
| JPWO2021021882A5 (https=) |